Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention.
about
Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatmentEndocrine FGFs: Evolution, Physiology, Pathophysiology, and PharmacotherapyBile Acid diarrhea: prevalence, pathogenesis, and therapyColesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled studyReview article: bile acid diarrhoea - pathogenesis, diagnosis and managementDrug-induced liver injury in inflammatory bowel disease: 1-year prospective observational studySystematic review: the management of chronic diarrhoea due to bile acid malabsorption.Advances in understanding of bile acid diarrhea.Commentary: fibroblast growth factor 19 in patients with bile acid diarrhoeaThe response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.Validating biomarkers of treatable mechanisms in irritable bowel syndromeEffect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndromeRegulation of bile acid homeostasis by the intestinal Diet1-FGF15/19 axis.Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy.The role of bile acids in functional GI disorders.Bile acid malabsorption in inflammatory bowel disease.Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis.Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea.Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples.Bile acid disease: the emerging epidemic.The Farnesoid X Receptor: Good for BAD.Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.Mechanisms of triglyceride metabolism in patients with bile acid diarrhea.Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis.Diet1, bile acid diarrhea, and FGF15/19: mouse model and human genetic variants.Editorial: diagnosing bile acid diarrhoea with blood tests.Editorial: developing a stimulation test to identify FGF19 deficiency in bile acid diarrhoea.Chenodeoxycholic acid stimulated fibroblast growth factor 19 response - a potential biochemical test for bile acid diarrhoea.A positive SeHCAT test results in fewer subsequent investigations in patients with chronic diarrhoea.Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.Dissecting Molecular Mechanisms in Bile Acid Diarrhea.Diarrhea in Crohn’s disease: investigating the role of the ileal hormone fibroblast growth factor 19.Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea.Challenging current views on bile acid diarrhoea and malabsorption.Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.
P2860
Q26751193-EB2804E6-127C-4154-9E35-3D4910B18F68Q26781556-04A7D94B-8C4B-4358-AF21-8F623D94079AQ28086845-22C54816-1048-4A25-9F2E-CA538E338A86Q28242569-DE027CDD-8395-434D-916D-5522E433C228Q28273649-B1987E94-B4A6-496E-B14D-0CD4316F7057Q33805921-7B453E0D-AA80-4793-B5DA-1AC7CDF413D4Q34408666-05B6963E-9B85-4959-8F01-637DE64CA208Q34412381-F787A363-608E-400A-80F1-888C9538C8B2Q34426461-224412D0-7FFB-4775-A338-E88CBA30E521Q34444158-A574A72F-1481-4569-BC0E-51453ADCFE9BQ34577283-83931563-274B-4CE3-BFED-F305787B8906Q35825711-BD81E23D-A1C7-4428-BF65-BCF2E58D14A5Q35836340-9817E494-693B-465B-92F1-A29C0A0288D3Q38198859-9E1D2FF8-66A4-4E4D-8AE7-990368D849A9Q38217671-9B19A42D-36AE-4402-9DC3-0C07399052A4Q38253467-0DBE323A-9633-4933-96AA-06961A9B5662Q38445280-54FE0408-79DB-4480-A629-9E422A33C048Q38582664-7E27E506-9561-497A-92B7-D7C807D1D8E6Q38687017-07DF3775-CD54-42FD-B884-0F62D2A2CEDFQ38699388-75D7F2F8-B37C-46C9-B735-E7FFEB536EAFQ39124316-C9264A6E-A491-4345-BD48-4EA685E90DEBQ39125255-BF5E6D46-A3B6-407E-ADCF-63563AB2DAC2Q39208620-241E1327-E83D-4549-9613-F78B422E328CQ39444895-E4FB8677-99B5-44EF-AEFB-969EA36289ABQ43270593-3512716E-6BD8-40F8-9C2E-3F2E68BE6B41Q47237068-53BFB314-4878-4417-9FA2-7D9AD5B829B4Q48112817-A7E57321-2AB4-4F68-89E5-244F06CF54FFQ48315900-702946DD-1C63-4BD5-86F4-CE3159A8C16CQ48319424-67B92BAD-A088-4D64-A44C-A571A88D6325Q50079125-0512240A-256A-4964-B45D-8222068C4C06Q50535134-6B7B4D2D-554D-4F8D-8DDB-B1A02C78C859Q51286764-5CBB47F1-0A0B-4DDD-AB20-C526E6F8040FQ51310817-03801723-D3BD-4591-9B35-BFEAC9CC5EDBQ51318198-60367C4C-849F-4951-BC5D-2C7EAF848226Q52626566-4D0C0211-3EA1-47FB-B757-C2FFE4757985Q55345479-A634E674-4459-405F-AC8E-5AB877DE2BB3
P2860
Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.
@ast
Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.
@en
Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.
@nl
type
label
Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.
@ast
Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.
@en
Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.
@nl
prefLabel
Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.
@ast
Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.
@en
Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.
@nl
P2093
P2860
P356
P1476
Fibroblast growth factor 19 in ...... um assay and SeHCAT retention.
@en
P2093
I M Johnston
J R F Walters
K D Bardhan
M Srinivas
P Basumani
S S Pattni
W G Brydon
P2860
P304
P356
10.1111/APT.12466
P407
P577
2013-08-27T00:00:00Z